ES2092172T3 - Compuestos de quinolina como antagonistas de la angiotensina ii. - Google Patents

Compuestos de quinolina como antagonistas de la angiotensina ii.

Info

Publication number
ES2092172T3
ES2092172T3 ES93107366T ES93107366T ES2092172T3 ES 2092172 T3 ES2092172 T3 ES 2092172T3 ES 93107366 T ES93107366 T ES 93107366T ES 93107366 T ES93107366 T ES 93107366T ES 2092172 T3 ES2092172 T3 ES 2092172T3
Authority
ES
Spain
Prior art keywords
angiotensin
antagonists
quinoline compounds
represented
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93107366T
Other languages
English (en)
Inventor
Yoshihisa Inoue
Hajime Ebisu
Naomichi Ishida
Norifumi Nakamura
Jun Sasaki
Takashi Okazoe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AGC Inc
Tanabe Pharma Corp
GC Biopharma Corp
Original Assignee
Asahi Glass Co Ltd
Green Cross Corp
Green Cross Corp Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Glass Co Ltd, Green Cross Corp, Green Cross Corp Korea filed Critical Asahi Glass Co Ltd
Application granted granted Critical
Publication of ES2092172T3 publication Critical patent/ES2092172T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PRESENTAN COMPUESTOS DE QUINOLINA REPRESENTADO POR LA FORMULA (1) O UNA SAL DE LOS MISMOS: EN DONDE Q ESTA REPRESENTADO POR LAS FORMULAS (2) O (3) EN DONDE R6 ES UN GRUPO ACIDICO, LOS COMPUESTOS PRESENTAN ANTAGONISMO HACIA LA ANGIOTENSINA II Y TIENEN UNA ACCION HIPOTENSORA Y SON UTILES COMO AGENTES PARA LA PREVENCION Y EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA CARDIOVASCULAR TALES COMO LA HIPERTENSION, EL FALLO CARDIACO Y SIMILARES.
ES93107366T 1992-05-08 1993-05-06 Compuestos de quinolina como antagonistas de la angiotensina ii. Expired - Lifetime ES2092172T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14340792 1992-05-08
JP17618892 1992-06-10

Publications (1)

Publication Number Publication Date
ES2092172T3 true ES2092172T3 (es) 1996-11-16

Family

ID=26475148

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95116041T Expired - Lifetime ES2121273T3 (es) 1992-05-08 1993-05-06 Compuestos de quinolina.
ES93107366T Expired - Lifetime ES2092172T3 (es) 1992-05-08 1993-05-06 Compuestos de quinolina como antagonistas de la angiotensina ii.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES95116041T Expired - Lifetime ES2121273T3 (es) 1992-05-08 1993-05-06 Compuestos de quinolina.

Country Status (8)

Country Link
US (3) US5478832A (es)
EP (2) EP0693478B1 (es)
KR (1) KR100227437B1 (es)
CA (1) CA2095680A1 (es)
DE (2) DE69320371T2 (es)
DK (2) DK0569013T3 (es)
ES (2) ES2121273T3 (es)
TW (1) TW369533B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
FR2699174B1 (fr) * 1992-12-14 1995-01-20 Synthelabo Dérivés de 3-(quinoléin-6-yl-méthyl)-4H-imidazol-4-one, leur préparation et leur application en thérapeutique.
FR2710914B1 (fr) * 1993-10-04 1995-11-24 Synthelabo Dérivés de 2-[2-(tétrazol-5-yl)phényl]-1,2-dihydroquinoléine, leur préparation et leur utilisation comme intermédiaires de synthèse.
FR2716196B1 (fr) * 1994-02-16 1996-04-05 Synthelabo Dérivés de 8-[2-(1H-tétrazol-5-yl) phényl] quinoléine, leur préparation et leur application en thérapeutique.
EP0709377B1 (en) * 1994-10-27 1999-09-29 Asahi Glass Company Ltd. Process for producing quinolin-2-yl benzoic acid compounds
JPH0959277A (ja) * 1995-08-17 1997-03-04 Green Cross Corp:The ６−アミノメチル置換キノリン安息香酸類の製造方法
JPH09202774A (ja) * 1996-01-25 1997-08-05 Green Cross Corp:The ２−アリールキノリン類およびその製造方法
JPH101471A (ja) * 1996-06-13 1998-01-06 Green Cross Corp:The Ｎ−［（キノリン−２−イル）フェニル］スルホンアミド類の結晶およびその製造方法
CA2264101A1 (en) * 1996-08-30 1998-03-05 Yoshitomi Pharmaceutical Industries Ltd. Preventives/remedies for muscle tissue degenerations
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7312044B2 (en) 2003-03-07 2007-12-25 The Trustees Of Columbia University In The City Of New York Type 1 ryanodine receptor-based methods
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7208502B2 (en) * 2002-01-18 2007-04-24 Maniv Energy Capital Methods of treating conditions associated with an Edg-3 receptor
EP1541149A1 (en) * 2002-06-26 2005-06-15 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US20040167181A1 (en) * 2003-01-16 2004-08-26 David Solow-Cordero Methods of treating conditions associated with an Edg-3 receptor
DK1641780T3 (da) * 2003-06-24 2009-02-02 Pfizer Prod Inc Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
CA2739060C (en) * 2008-10-15 2016-08-23 Kissei Pharmaceutical Co., Ltd. Fused-ring derivative and medical application of same
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
HK1213887A1 (zh) 2012-10-16 2016-07-15 Janssen Pharmaceutica N.V. RORγt的苯基连接的喹啉基调节剂
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CA2926339A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of roryt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
CR20180109A (es) 2015-07-20 2018-05-03 Genzyme Corp Inhibidores de receptor del factor estimulador de colonias 1 (csf-1r)
US11530216B2 (en) * 2020-12-23 2022-12-20 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
DK0528762T3 (da) * 1991-08-15 1997-08-25 Ciba Geigy Ag N-acyl-N-heterocyclyl- eller naphthylalkyl-aminosyrer som angiotensin II antagonister
US5371227A (en) * 1991-10-28 1994-12-06 Synthelabo Quinoline derivatives, process for their preparation, and their therapeutic applications
FR2683819B1 (fr) * 1991-10-28 1994-02-11 Synthelabo Derives de quinoleine, leur procede de preparation et leur application en therapeutique.
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds

Also Published As

Publication number Publication date
KR100227437B1 (ko) 1999-11-01
DK0569013T3 (da) 1996-09-16
EP0569013B1 (en) 1996-08-28
EP0693478B1 (en) 1998-08-12
EP0569013A1 (en) 1993-11-10
DK0693478T3 (da) 1999-05-10
US5478832A (en) 1995-12-26
ES2121273T3 (es) 1998-11-16
DE69304243D1 (de) 1996-10-02
TW369533B (en) 1999-09-11
US5665881A (en) 1997-09-09
US5780634A (en) 1998-07-14
KR940005566A (ko) 1994-03-21
CA2095680A1 (en) 1993-11-09
EP0693478A1 (en) 1996-01-24
DE69304243T2 (de) 1997-03-06
DE69320371T2 (de) 1999-01-28
DE69320371D1 (de) 1998-09-17

Similar Documents

Publication Publication Date Title
EA199700117A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов
ECSP941135A (es) Antagonistas triciclicos de vasopresina de benzacepina
AR029417A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
UY23835A1 (es) Procedimiento para la preparacion de compuesto de acilo
ES2063734T3 (es) Imidazoles bloqueantes de receptores de angiotensina ii.
CA2122236A1 (en) Quinolines and their analogs
DK0807633T3 (da) Hidtil ukendte 2,3-disubstituerede-(5,6)-heteroarylkondenserede pyrimidin-4-oner
AR002459A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
DE69200160D1 (de) Angiotensin-II-Antagonisten.
EA199900161A1 (ru) Производные пиридазино [4,5-в]-хинолин-5-оксида, их получение и применение в качестве антагонистов глицина
ES2106616T3 (es) Derivados de 11,21-bisfenilo-19-nor-pregnanos.
ATE324890T1 (de) Zusammensetzung enthaltend einen angiotensin-ii- rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck
ES2136291T3 (es) Derivados de pirimidina.
ATE399011T1 (de) Substituierte diketopiperazine als oxytocin- antagonisten
ES2127789T3 (es) Derivados de 1,2,4-triazol 4-sustituidos.
FI102964B1 (fi) Terapeuttisia yhdisteitä
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
EA200200562A1 (ru) Антагонисты аденозиновых рецепторов и способы их получения и использования
DE69029693D1 (de) Hydantoin- oder Imidazolidintrionderivate zur Vorbeugung oder Behandlung von Niereninsuffizienz
ATE295183T1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
NO158379C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive nitroalifatiske forbindelser.
NO885655L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-methylpyrrolidin- og fucitolderivater.
DE3774273D1 (de) Chinazolin-derivat, verfahren zu dessen herstellung und mittel zur behandlung von cerebraler disfunktion als aktiver inhaltsstoff.
ES2081834T3 (es) Pirrolidin-2-onas 4-metil y 4-etil sustituidas.
ES2095985T3 (es) Analogos de fosfato de inositol como sustancias antagonistas del calcio.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 569013

Country of ref document: ES